|
Carcinoma of lung
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Simultaneous amplification of epidermal growth factor-receptor and multidrug-resistance genes in a newly. Established human lung cancer cell line.
|
2018357 |
1991 |
|
Carcinoma of lung
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of the epidermal growth factor receptor has been noted in many types of tumors and is associated with gene amplification in several including epidermoid carcinoma, lung carcinoma, breast carcinoma and glioblastoma.
|
2294252 |
1990 |
|
Carcinoma of lung
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Epidermal growth factor receptor expression in human lung cancer cell lines.
|
2830015 |
1988 |
|
Carcinoma of lung
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Methylation status of epidermal growth factor receptor gene in lung carcinoma cells.
|
2848004 |
1988 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
We have determined the average gene copy numbers (AGCN) of the erbB-1 gene, encoding the epidermal growth factor receptor (EGF-R), the erbB-2 and the erbB-3 genes in breast, ovarian, oral, and lung cancer tissue by using double-differential PCR (ddPCR).
|
7607571 |
1995 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The type III EGFR deletion mutant, expressed in some cases of NSCLC, may be a molecularly defined, tumor-specific antigen in lung cancer.
|
8391918 |
1993 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
The LC with SSCP p53 molecular abnormalities have a significantly higher EGFR content (P < 0.001), SPF (P < 0.007), D.I.
|
9498104 |
1998 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group.
|
10190311 |
1999 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
We added these compounds to a human ovarian carcinoma cell line (SKOV3) and a human lung carcinoma line (A549), both of which overexpress the EGFR.
|
10206071 |
1999 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Over-expression of truncated epidermal growth factor receptor (EGFR) occurs in a variety of malignancies including glioblastoma multiforme, breast and lung cancer.
|
11355942 |
2001 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Evidence for the epidermal growth factor receptor as a target for lung cancer prevention.
|
11801540 |
2002 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor family in lung cancer and premalignancy.
|
11894009 |
2002 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
The authors have previously shown that DAB(389)EGF is selectively toxic to EGFR-overexpressing cells, including human brain tumour and lung carcinoma cell lines.
|
14519080 |
2003 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Overexpression of the epidermal growth factor receptor (EGFR) has been identified as a common component of various cancer types including lung cancer.
|
14534727 |
2004 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Because the ErbB receptors play an important role in lung cancer progression, we analyzed the expression of epidermal growth factor receptor (EGFR), phosphorylated EGFR, transforming growth factor alpha (TGFalpha), and HER2-neu as potential prognostic factors in stage I NSCLC.
|
14734462 |
2004 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Treatment of the glioblastoma cell line U373-MG and the lung carcinoma cell line NCI-H292 with nanomolar concentrations of THC led to accelerated cell proliferation that was completely dependent on metalloprotease and epidermal growth factor receptor (EGFR) activity.
|
15026328 |
2004 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P<0.001).
|
15118073 |
2004 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
EGFR mutations were found in additional lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.
|
15118125 |
2004 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
In this article, we review the role of EGFR in lung cancer, as well as preclinical and clinical data on strategies to interfere with EGFR signaling alone or in combination with chemotherapy, radiation, or both.
|
15217533 |
2004 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
The biology of epidermal growth factor receptor in lung cancer.
|
15217963 |
2004 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
|
15284455 |
2004 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
|
15604253 |
2004 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
The recent identification of somatic mutations in the epidermal growth factor receptor (EGFR)-tyrosine kinase (TK) domain of tumor samples from patients with non-small-cell lung cancer (NSCLC) that portend robust response to small-molecule inhibitors of EGFR TK is a watershed event in the fields of lung cancer genetics and therapeutic agents.
|
15638956 |
2004 |
|
Carcinoma of lung
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We therefore investigated lung cancer cell lines for alterations in EGFR gene copy number, enhanced expression of EGFR and other HER family members, and EGFR coding sequence mutations and correlated these findings with response to treatment with the EGFR inhibitors and the kinetics of ligand-induced signaling.
|
15665299 |
2005 |